Ablynx: Corporate Presentation (Ablynx) - Feb 20, 2013 - "Efficacious: ACR20, ACR50 and ACR70 scores of up to 100%, 75% and 63%, respectively"; "Up to 75% of patients in DAS28 remission"; "Up to 38% of patients in boolean remission"; "First onset of remission as of week 2"; "Early signs of effect on bone oedema"; "No disease progression as determined by MRI"; "Wide therapeutic window with option to dose every two months"; "Well-tolerated and favourable safety profile across all doses"
P2 data • Immunology • Rheumatoid Arthritis
|